Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case report.
Behçet's disease (BD) is a multisystem disorder characterized by vasculitis. Pulmonary vascular problems such as pulmonary artery aneurysms (PAA) are reported to indicate poor prognosis and high mortality. We describe a 43-year-old man who presented with life threatening bilateral PAA and thromboembolic disease due to BD. He was treated with prednisone and pulse cyclophosphamide and was poorly responsive to the conventional immunosuppression. The introduction of adalimumab therapy stabilized his PAA. We report that the inhibition of TNF-alpha using the neutralizing monoclonal antibody adalimumab has the potential to induce rapid, complete, and long-lasting remission in a life-threatening manifestation of BD.
Lee
Sung-Won
SW
Department of Internal Medicine, Dong-A University, College of Medicine, Busan, Korea. leesw@dau.ac.kr
Lee
Sang-Yeob
SY
Kim
Ki-Nam
KN
Jung
Jin-Kyu
JK
Chung
Won-Tae
WT
D000068879:Adalimumab; D000328:Adult; D000783:Aneurysm / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001528:Behcet Syndrome / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011651:Pulmonary Artery / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D000068879:Adalimumab; D011241:Prednisone